首页|药物代谢产物在质量标准中可接受限度探讨

药物代谢产物在质量标准中可接受限度探讨

扫码查看
对小分子创新药中代谢产物作为有关物质,在质量标准中如何设定其限度进行探讨。通过对各个相关指导原则的分析解读,结合FDA和EMA的审评案例,找出杂质界定的条件,再基于多批检测结果,生产和贮藏过程的增量,制定杂质的可接受限度。
Discussion on acceptance limit of drug metabolites in quality standard
This paper discussed how to set the limit of impurities in the quality standard when the impurities in small-molecular innovative drugs were metabolites.Firstly,through the analysis and interpretation of each relevant guideline,in combination with the review cases of FDA and EMA,found out the conditions for qualification of im-purity,and then establ ish the acceptable limit of impurities based on the test results of multiple batches,the incre-ments of production process and storage process.

related substancemetabolitesqualificationacceptable limitquality standardimpurity

刘云飞、王凌波、吴秀兰、于佳、周浩、杨利红

展开 >

正大天晴药业集团股份有限公司,南京 211112

黑龙江省药品检验研究院,哈尔滨 150088

有关物质 代谢产物 界定 可接受限度 质量标准 杂质

2024

中国药品标准
国家药典委员会

中国药品标准

影响因子:0.372
ISSN:1009-3656
年,卷(期):2024.25(5)